REQUEST A DEMO
Total
USD $0.00
Search more companies

Nilsan Pharmaceuticals Private Limited (India)

Main Activities: Architectural Services
Full name: Nilsan Pharmaceuticals Private Limited Profile Updated: March 06, 2026
Buy our report for this company USD 29.95 Most recent financial data: 2025 Available in: English Download a sample report

Nilsan Pharmaceuticals Private Limited is based in India. The head office is in North West Delhi. The company operates in the Architectural Services sector. The company was established on July 18, 1996. From the latest financial highlights, Nilsan Pharmaceuticals Private Limited reported a net sales revenue drop of 10.21% in 2025. There was a total growth of 5.66% in Nilsan Pharmaceuticals Private Limited’s total assets over the same period. The net profit margin of Nilsan Pharmaceuticals Private Limited increased by 1.16% in 2025.

Legal Address
Unit No B , Basement Floor , Vardhman Grand Plaza , Manglam Palace, Sector 3
North West Delhi; Delhi; Postal Code: 110085

Contact Details: Purchase the Nilsan Pharmaceuticals Private Limited report to view the information.

Basic Information
Registered Capital:
Purchase the Nilsan Pharmaceuticals Private Limited report to view the information.
Financial Auditors:
Purchase the Nilsan Pharmaceuticals Private Limited report to view the information.
Incorporation Date:
July 18, 1996
Key Executives
Purchase this report to view the information.
Promoter Director
Purchase this report to view the information.
Professional Director
Company Performance
Financial values in the chart are available after Nilsan Pharmaceuticals Private Limited report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency INR. Absolute financial data is included in the purchased report.
Net sales revenue
-10.21%
Total Operating Revenue
-8.82%
Operating Profit
21.98%
EBITDA
16.17%
Net Profit/Loss for the Period
96.71%
Total Assets
5.66%
Total Equity
19.95%
Operating Profit Margin
1.9%
Net Profit Margin
1.16%
Return on Equity (ROE)
6.49%
Debt / Equity
79%
Quick Ratio
0.02%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?